Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

70.05USD
3:27pm EST
Change (% chg)

$0.04 (+0.06%)
Prev Close
$70.01
Open
$69.90
Day's High
$70.25
Day's Low
$69.80
Volume
480,224
Avg. Vol
709,823
52-wk High
$70.25
52-wk Low
$45.48

Latest Key Developments (Source: Significant Developments)

Baxter announces U.S. FDA approval, commercial launch of ready-to-use clindamycin injection in saline
Wednesday, 7 Jun 2017 11:00am EDT 

June 7 (Reuters) - Baxter International Inc :Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline.Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline.Baxter International - FDA approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations.Baxter International Inc- remains committed to providing additional premixes in an effort to advance pharmacy efficiency and patient care..Baxter International Inc - Baxter's ready-to-use clindamycin injection in saline is now available to customers in United States.  Full Article

Baxter and Mayo Clinic launch R&D collaboration to transform patient care
Wednesday, 31 May 2017 09:15am EDT 

May 31 (Reuters) - Baxter International Inc :Baxter and Mayo Clinic launch research and development collaboration to transform patient care.Baxter International Inc - ‍additional details of agreement were not disclosed​.Baxter International Inc - initial agreement is for a five-year period, with a five-year renewal option.  Full Article

Baxter International says in April became aware of criminal investigation by antitrust division of DOJ- SEC filing
Thursday, 4 May 2017 07:01pm EDT 

May 4 (Reuters) - Baxter International Inc ::in April 2017, co became aware of criminal investigation by U.S. DOJ, antitrust division and federal jury in U.S. District court for eastern district of Pennsylvania-filing.co and employee received subpoenas regarding manufacturing, selling, pricing and shortages of intravenous solutions and containers.  Full Article

Baxter International says received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology
Wednesday, 3 May 2017 08:30am EDT 

May 3 (Reuters) - Baxter International Inc :Baxter International Inc - received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology.Baxter International Inc - Baxter plans to have first patient on therapy with new system, as part of a clinical trial in 2018.Baxter International Inc - regulatory submission is expected in 2019 for new peritoneal dialysis technology.  Full Article

Baxter raises quarterly dividend
Tuesday, 2 May 2017 08:30am EDT 

May 2 (Reuters) - Baxter International Inc : :Increases quarterly dividend by 23 percent.Baxter raises quarterly dividend.Baxter International Inc - sets qtrly dividend of 13 cents per share.  Full Article

Baxter International Q1 revenue $2.5 billion
Wednesday, 26 Apr 2017 07:15am EDT 

April 26 (Reuters) - Baxter International Inc :Baxter reports first-quarter 2017 results and increases financial outlook for full-year 2017.Q1 GAAP earnings per share $0.50 from continuing operations.Q1 revenue $2.5 billion versus I/B/E/S view $2.43 billion.Q1 earnings per share view $0.51 -- Thomson Reuters I/B/E/S.Sees FY 2017 earnings per share $2.20 to $2.28 from continuing operations excluding items.Sees FY 2017 GAAP earnings per share $1.66 to $1.80.In Q2, expects flat sales growth on a reported basis, or approximately 2 percent on a constant currency basis.FY2017 earnings per share view $2.17 -- Thomson Reuters I/B/E/S.Baxter International - now expects sales growth of approximately 1 to 2 percent on a reported basis or 2 to 3 percent on a constant currency basis in 2017.Baxter International - expects sales growth of about 1 to 2 percent on a reported basis or 2 to 3 percent on a constant currency basis for FY 2017.Baxter International says expects earnings from continuing operations, before special items, of $0.55 to $0.57 per diluted share in Q2.Qtrly adjusted earnings of $0.58 per share.Q2 earnings per share view $0.52, revenue view $2.56 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $2.17, revenue view $10.20 billion -- Thomson Reuters I/B/E/S.  Full Article

Third Point sells 5.9 mln shares of Baxter International's common stock in block trade on Feb 28
Wednesday, 1 Mar 2017 11:44am EST 

: Third Point LLC says on Feb 28, it sold about 5.9 mln shares of Baxter International Inc's common stock in a block trade at $50.35 per share . Third Point LLC now owns about 46 million shares of Baxter International's common stock as of feb 28 - sec filing . Third Point LLC previously owned 51.9 million shares of Baxter International's common stock as of Dec 31, 2016 according to its 13-F filing disclosed in Feb .Third Point​ now owns 8.5 pct stake in Baxter International following the block trade.  Full Article

Baxter and Scinopharm announce partnership for generic oncology injectables
Tuesday, 28 Feb 2017 08:00am EST 

Baxter International Inc : Baxter and Scinopharm announce exclusive strategic partnership for generic oncology injectables . Baxter International Inc - under terms of partnership, Baxter and Scinopharm will collaborate on product development and manufacturing .Baxter International Inc - Baxter will hold commercialization rights, with products included in arrangement expected to launch beginning in 2020.  Full Article

Baxter debuts enteral nutrition ENFit syringe and accessory line in clinical nutrition week 2017
Thursday, 16 Feb 2017 08:30am EST 

Baxter International Inc - : Baxter debuts enteral nutrition ENFit syringe and accessory line during clinical nutrition week 2017 . Expansion of nutrition care portfolio to include new enteral ENFit syringe, accessory line for patients requiring tube feeding .Plans to launch its enteral ENFit syringes, accessories in US , Canada, select European countries, Australia, New Zealand in 2017.  Full Article

Baxter International reports Q4 earnings per share of $0.44
Wednesday, 1 Feb 2017 07:30am EST 

Baxter International Inc : Baxter reports 2016 fourth-quarter and full-year results . Sees Q1 2017 earnings per share $0.50 to $0.52 from continuing operations excluding items . Baxter International Inc says fourth-quarter revenue of $2.6 billion increased 2 percent on a reported and constant currency basis . Baxter International Inc says fourth-quarter GAAP earnings per share of $0.44; adjusted earnings per share of $0.57 increased 33 percent . Baxter International - worldwide sales totaled $2.6 billion in Q4, increase of 2 percent on reported and constant currency basis versus prior-year period . Baxter -renal sales totaled $1 billion in Q4, representing a 3 percent increase on a reported basis, and a 5 percent increase on a constant currency basis . Baxter International Inc sees Q1 GAAP earnings per share $0.39 - $0.42 . Baxter International - for FY 2017, expects sales to be comparable to prior-year period on reported basis, increase about 2 percent on constant currency basis . Baxter International Inc - for Q1, company expects sales growth of approximately 2 to 3 percent on a reported basis . Baxter International Inc sees Q1 adjusted earnings per share $0.50 - $0.52 . Baxter International Inc - expects earnings from continuing operations, before special items, of $2.10 to $2.18 per diluted share for full-year 2017 . Says expects 2017 underlying constant currency sales growth of approximately 4 percent.  Full Article

BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin

* BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN